1y return+145.4%S&P 500 +20.9%
3y return+138.1%S&P 500 +68.5%
These returns are for its stock picks as disclosed on Form 13F: last quarter's holdings, valued at this quarter's prices. They miss trades within each quarter, short positions, options, bonds, cash and fees, so they aren't the returns its clients got.
$100 invested in its stock picks
Since December 31, 2022: $233 against $195 in the S&P 500.2
Atlas Venture Life Science Advisors, LLCS&P 500 (SPY)
Top holdings
At the end of June 30, 2026. Change is in shares since the quarter before.2
| Stock | Value | Share of portfolio | Change |
|---|---|---|---|
| KYMRKymera Therapeutics, Inc. | $326.5M | 37.1% | −37.8% |
| DYNDyne Therapeutics, Inc. | $151.0M | 17.1% | −25.5% |
| SIONSionna Therapeutics, Inc. | $131.8M | 15.0% | |
| KLRAKailera Therapeutics, Inc. | $113.9M | 12.9% | New |
| IRONDisc Medicine, Inc. | $110.7M | 12.6% | |
| QTTBQ32 Bio, Inc. | $34.6M | 3.9% | +29.9% |
| KRROKorro Bio, Inc. | $12.7M | 1.4% | −15.3% |
Best picks still held
How each current holding has done since the quarter it first appeared in its filings (up to six years back).
| Stock | Held since | Return since | Now worth |
|---|---|---|---|
| SIONSionna Therapeutics, Inc. | March 31, 2025 | +320.6% | $131.8M |
| IRONDisc Medicine, Inc. | December 31, 2022 | +267.7% | $110.7M |
| DYNDyne Therapeutics, Inc. | December 31, 2021 | +86.8% | $151.0M |
| KYMRKymera Therapeutics, Inc. | December 31, 2021 | +80.6% | $326.5M |
Quarter by quarter
| Quarter | Its picks | S&P 500 |
|---|---|---|
| June 30, 2026 | +28.1% | +14.8% |
| March 31, 2026 | +8.6% | −4.6% |
| December 31, 2025 | +36.8% | +2.4% |
| September 30, 2025 | +29.0% | +7.8% |
| June 30, 2025 | +21.4% | +10.5% |
| March 31, 2025 | −41.5% | −4.6% |
| December 31, 2024 | −15.4% | +2.1% |
| September 30, 2024 | +18.5% | +5.4% |
| June 30, 2024 | −8.3% | +4.0% |
| March 31, 2024 | +39.3% | +10.0% |
| December 31, 2023 | +24.3% | +11.2% |
| September 30, 2023 | −14.1% | −3.6% |
| June 30, 2023 | +9.1% | +8.3% |
| March 31, 2023 | −10.4% | +7.0% |
| September 30, 2022 | +13.0% | −5.3% |
| June 30, 2022 | −24.2% | −16.5% |
| March 31, 2022 | −31.1% | −4.9% |
Sources
Every number on this page points here. Each one links to the public record.
- 1SEC EDGAR: Atlas Venture Life Science Advisors, LLC Form 13F filingshttps://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1917529&type=13F-HR&dateb=&owner=include&count=40CIK 1917529
- 2SEC: 13F for the quarter ended June 30, 2026https://www.sec.gov/Archives/edgar/data/1917529/000110465926095933/Filed August 13, 2026 · accession 0001104659-26-095933